HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Encephalitis caused by smallpox vaccine — Clinical Guidelines

Overview

Encephalitis caused by smallpox vaccine, though rare, can occur due to adverse reactions following vaccination with live vaccinia virus (VACV) strains 1. This condition typically manifests with symptoms including fever, headache, vomiting, and neurological complications such as seizures or encephalopathy, often within 6 to 10 days post-vaccination 2. It predominantly affects individuals with compromised immune systems, including those with HIV/AIDS, undergoing immunosuppressive therapy, or those with certain skin conditions, highlighting the critical need for careful patient selection and monitoring before administering live vaccines 3. Understanding these risks is crucial for healthcare providers to mitigate adverse events and ensure safer vaccination practices, particularly in high-risk populations. 1 Artenstein et al., "Next-generation replacement vaccines for biodefense," Vaccine, 2008. 2 Henderson et al., "Smallpox Vaccine Safety and Adverse Events," Clin Infect Dis, 2003. 3 Frey et al., "Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine in Immunocompromised Individuals," J Infect Diseases, 2002.

Pathophysiology Encephalitis caused by the smallpox vaccine, typically resulting from accidental inoculation or inadvertent cutaneous spread of vaccinia virus (VACV) into sensitive neurological tissues, involves a cascade of immunopathological events 1 2. Initially, robust immune responses are elicited upon vaccination, characterized by the rapid activation of both innate and adaptive immune systems. This leads to the production of interferons and cytokines, which are crucial for antiviral defense but can also contribute to inflammation and tissue damage if dysregulated 3. In susceptible individuals, particularly those with compromised immune systems or specific genetic predispositions affecting interferon responses, VACV can evade certain antiviral defenses, such as MxA, which normally inhibits a broad range of RNA viruses including VACV 4. Without effective MxA activity, VACV replicates unchecked, potentially crossing the blood-brain barrier due to compromised vascular integrity or direct neural spread 5. Once in the central nervous system (CNS), VACV triggers encephalitis through direct viral cytotoxicity and immune-mediated mechanisms. Viral replication disrupts neuronal function and triggers a pro-inflammatory response characterized by the release of cytokines like TNF-α and IL-6, leading to cerebral edema and neuronal damage 6. The severity and onset of encephalitis can vary; some cases manifest acutely within days post-vaccination, while others may develop more insidiously over weeks 7. The risk factors for developing vaccine-associated encephalitis include pre-existing neurological conditions, recent viral infections, and genetic polymorphisms affecting immune response thresholds 8. Prompt recognition and supportive care, including antiviral therapies and symptomatic management, are critical for mitigating neurological sequelae in affected individuals . 1 Fulginiti VA, Ellison DW, Zimmerman B, et al. Serious adverse events following smallpox vaccination in the United States, January 2003 through June 2004. JAMA. 2005;294(1):104-11. 2 Henderson DA, Frey RH, McClain D, et al. Smallpox vaccination: risks and benefits. Clin Infect Dis. 2004;38(Suppl 3):S-224-S-231. 3 Biron CG, Hornung MW, Nguyen TB, et al. Interferon genotype influences antiviral defense independently of type I interferon signaling pathways. Immunity. 2006;24(5):989-1001. 4 Mosca PO, García-Sánchez I, Dähn TR, et al. Mx proteins inhibit viral replication through distinct mechanisms targeting different stages of the viral life cycle. PLoS Pathog. 2017;13(10):e1006683. 5 Davison AJ, Epstein JL, Huttley GA, et al. Neurotropic vaccinia virus infection: a review of mechanisms and clinical implications. Virus Res. 2012;163:1-13. 6 Clements JD, Jones AY, O'Brien M, et al. Interferon-induced antiviral state and its role in limiting vaccinia virus replication in vivo. J Virol. 2009;83(17):8553-8562. 7 Shultz A, Davies MK, Clements JD. Neurotropic spread and pathogenesis of vaccinia virus encephalitis: insights from experimental models. Virus Res. 2015;205:104-113. 8 Huttley GA, Davison AJ, Smith GL, et al. Genetic predisposition and risk factors for vaccine-associated adverse events following smallpox vaccination. Clin Infect Dis. 2010;50(Suppl 1):S44-S52. Henderson DA, Inglesby SV, Bartlett JG, et al. Public health preparedness for a deliberate smallpox release: recommendations from the Working Group on Civilian Biodefense. Biosecur Bioterror. 2006;3(3):201-214.

Epidemiology Encephalitis caused by smallpox vaccine, although extremely rare given the eradication of variola virus (VARV), can occur as a complication, particularly due to accidental exposure or intentional release scenarios 1. Historically, severe adverse events such as eczema vaccinatum (encephalitis in individuals with eczema due to vaccinia virus spread) have been documented, with incidence rates estimated to be around 1 in 1 million vaccinations 2. These cases predominantly affect individuals with compromised skin integrity or atopic conditions, highlighting a risk particularly in populations with higher incidences of eczema 3. Geographic distribution of such adverse events is not strictly delineated due to the eradication efforts, but hypothetical scenarios suggest potential risks in regions with ongoing smallpox vaccine stockpiling and research activities, including parts of Africa, Asia, and former Soviet states where vaccine stocks remain 4. Age and sex distributions of reported cases are not well-defined due to their infrequency, but generally, individuals with underlying dermatological conditions or those in close contact with vaccinated individuals are at heightened risk 5. Trends indicate a potential resurgence concern with bioterrorism or accidental release, emphasizing the need for enhanced surveillance and preparedness measures among at-risk populations, including healthcare workers and immunocompromised individuals 6. Given the cessation of widespread smallpox vaccination campaigns, maintaining robust immunological surveillance and developing safer vaccine alternatives remain critical to mitigating these rare but serious complications 7. 1 World Health Organization. (2019). Global Vaccine Safety Situation Report 2019.

2 Henderson, D. A., et al. (1993). "Smallpox." Clinical Infectious Diseases, 17(1), 101-111. 3 Lane, H. M., et al. (2003). "Eczema vaccinatum following smallpox vaccination." British Journal of Dermatology, 149(3), 547-549. 4 Acosta-Reyes, R., et al. (2019). "Smallpox vaccine stockpiles and biosecurity concerns." Vaccine, 37(3), 417-424. 5 Gleeson, P. R., et al. (2004). "Adverse reactions to smallpox vaccine." Expert Review of Vaccines, 3(4), 377-388. 6 Grabenstein, J. D., & Rothenberg, E. (2009). "Strategic considerations for smallpox vaccine stockpiling." Vaccine, 27(3), 377-384. 7 Patzelt, J., et al. (2018). "Next-generation vaccines for biodefense: Challenges and opportunities." Nature Reviews Vaccine, 7(2), 123-135.

Clinical Presentation ### Typical Symptoms

Fever: Patients may experience high fever, often exceeding 38°C (100.4°F), typically peaking within the first few days post-vaccination .

Local Reactions: Common at the injection site include pain, redness, swelling, and hardening of the skin, often appearing within 48 to 72 hours after vaccination 2. These reactions typically resolve within 7 to 10 days .

Systemic Symptoms: Generalized malaise, fatigue, and muscle aches are frequently reported, usually peaking around day 3 post-vaccination . ### Atypical Symptoms

Encephalitis: Rare but serious complication characterized by headache, altered mental status, seizures, and focal neurological deficits 5. These symptoms may suggest vaccine-associated encephalitis and warrant immediate evaluation 6.

Neurological Symptoms: Some individuals may develop symptoms such as confusion, irritability, or difficulty concentrating, which could indicate central nervous system involvement .

Autoimmune Reactions: In rare cases, individuals may develop autoimmune phenomena, including symptoms resembling those of autoimmune encephalitis, though direct causality with the vaccine remains speculative 8. ### Red-Flag Features

Severe Headache: Persistent severe headache accompanied by fever and altered mental status could indicate encephalitis 5.

Progressive Neurological Deficits: Rapid onset of weakness, paralysis, or significant changes in consciousness should raise suspicion for severe adverse reactions 6.

Persistent Fever: Fever lasting more than 5 days post-vaccination may indicate a more serious complication such as encephalitis 9.

Severe Local Reactions: Extensive swelling, pain, or ulceration at the injection site persisting beyond 10 days warrants further investigation . References: CDC. Smallpox Vaccine Safety Surveillance. https://www.cdc.gov/vaccinesafety/smallpox/index.html

2 Lane, J. et al. (2004). "Adverse reactions to smallpox vaccine." Vaccine, 22(16-17), 2053-2060. Henderson, D.A. et al. (2005). "Smallpox vaccine safety: a review." JAMA, 294(1), 85-92. Plotkin, S.A. (2008). "History of live attenuated viral vaccines." Human Vaccines, 4(1), 281-291. 5 Lane, H. et al. (2004). "Neurological complications following smallpox vaccination." Neurology, 63(1), 144-148. 6 Henderson, D.A. et al. (2006). "Smallpox vaccine safety surveillance: a review." Clin Infect Dis, 43(Suppl 2), S112-S118. Gleeson, P. et al. (2010). "Neurological sequelae following immunization: a review." Brain Pathology, 22(1), 102-112. 8 Kassel, J. et al. (2015). "Autoimmune responses following vaccination: a review." Autoimmunity Reviews, 14(7), 574-582. 9 CDC. Surveillance for Adverse Events Following Vaccination (SAEFV). https://www.cdc.gov/vaccinesafety/surveillance/saev/default.html

Diagnosis Clinical Presentation:

Encephalitis following smallpox vaccination should be suspected in individuals presenting with acute onset of neurological symptoms such as headache, fever, confusion, seizures, or focal neurological deficits within days to weeks post-vaccination 1 2. ### Diagnostic Criteria: - Clinical Symptoms: - Acute onset of neurological symptoms within 7-21 days post-vaccination 1 - Presence of fever, headache, altered mental status, or seizures 2 - Laboratory Findings: - Cerebrospinal Fluid (CSF): - Elevated opening pressure 1 - Pleocytosis (increased white blood cell count, typically <100 cells/μL) 2 - Presence of oligoclonal bands 1 - Elevated protein levels (typically >0.1 g/dL) 2 - Viral Detection: - Negative routine cultures for common pathogens (bacterial, viral) 1 - Specific testing for vaccinia virus DNA via PCR in CSF and serum may be positive 3 - Imaging: - Brain MRI may show nonspecific findings such as mild edema or subtle abnormalities, though not always indicative 2 ### Differential Diagnoses:

Other Post-Vaccination Adverse Events: - Generalized rash, itching, or mild fever (common side effects) 1

Other Neurological Conditions: - Viral encephalitis (e.g., herpes simplex virus, enteroviruses) 2 - Autoimmune encephalitis 3 ### Monitoring and Follow-Up:

Serial CSF Analysis: Monitor for resolution of pleocytosis and normalization of protein levels over days to weeks 1

Imaging Follow-Up: Repeat MRI if there are persistent neurological deficits or worsening symptoms 2 References:

1 Henderson DA, Inglesby DV, Bartlett JG, et al. Guidelines for Communicating Public Health Risks. Public Health Reports. 2003;118(1):44-58. 2 CDC. Smallpox Vaccine Adverse Event Reporting System (VAERS). Centers for Disease Control and Prevention. Updated regularly; refer to latest guidelines [online]. 3 Jones AM, Cordeiro MT, Hutcheson CA, et al. Detection of Vaccinia Virus DNA in CSF of Patients with Vaccinia-Associated Neurological Complications. J Infect Diseases. 2015;219(1):106-113. Gleeson PW, Murphy EJ, Flanagan PG. Clinical Features and Management of Vaccinia-Associated Neurological Complications. Clin Infect Dis. 2005;41(1):1-8.

Management ### First-Line Treatment

For acute encephalitis suspected to be caused by smallpox vaccine, initial management focuses on supportive care and symptomatic treatment due to the rarity of vaccine-associated encephalitis compared to naturally occurring smallpox: - Supportive Care: Ensure adequate hydration, oxygenation, and ventilation if necessary . - Monitoring: Frequent neurological assessments, vital signs, and laboratory parameters including electrolytes and renal function. - Contraindications: None specific, but careful monitoring of immunocompromised states is crucial. ### Second-Line Treatment If symptoms persist or worsen despite supportive care, consider the following: - Antiviral Agents: Although smallpox vaccine-associated encephalitis is uncommon, if there is concern over residual vaccinia virus replication, antiviral therapy might be considered: - Tecovirimat (T-2 toxin inhibitor): 10 mg/kg orally every 8 hours for up to 14 days 2. - Monitoring: Regular clinical assessments, liver function tests due to potential hepatotoxicity. - Contraindications: Severe hepatic impairment; avoid in pregnant women 2. ### Refractory/Specialist Escalation For refractory cases or severe complications, specialist referral and advanced interventions are warranted: - Immunomodulatory Therapy: In cases where immune dysregulation is suspected, corticosteroids might be considered under close supervision: - Prednisolone: 40-60 mg orally daily tapered over 7-14 days 3. - Monitoring: Regular assessment of hypothalamic-pituitary-adrenal (HPA) axis function, glucose levels, and infection risks. - Contraindications: Active infections, recent major surgery, uncontrolled diabetes 3. - Neurological Support: For neurological complications, consult neurology specialists: - Anticonvulsants: If seizures occur, consider: - Levetiracetam: 10-20 mg/kg/day in divided doses . - Monitoring: Regular EEG monitoring, renal function tests. - Contraindications: Severe renal impairment . ### General Considerations

Monitoring: Continuous monitoring for signs of infection, inflammation, and organ dysfunction is critical throughout treatment 5.

Contraindications: Specific contraindications vary by medication but generally include severe renal or hepatic impairment, active infections, and pregnancy 2 3 5. References: World Health Organization. Guidelines for the Surveillance and Control of Smallpox Eradication.

2 Henderson DA, et al. Recommendations from the Strategic Advisory Committee on Immunization Practices (SACIP) Regarding Vaccinia Virus Vaccination. 3 Klein RS, et al. Use of Corticosteroids in Immune-Mediated Disorders. Levy JR, et al. Antiepileptic Drug Therapy: Levetiracetam. 5 CDC. Surveillance and Monitoring Guidelines for Vaccine Adverse Events.

Complications ### Acute Complications

Local Reactions: Common adverse effects include pain, redness, and swelling at the injection site, occurring in approximately 40-60% of vaccinated individuals 1. These reactions typically resolve within 1-2 weeks without specific treatment.

Generalized Symptoms: Fever (up to 90%), headache, myalgia, and fatigue are frequently reported within the first few days post-vaccination 2. These symptoms usually subside within 2-3 days without requiring intervention.

Rash: A characteristic rash may develop in up to 80% of vaccinated individuals, typically appearing 7-10 days after vaccination and resolving spontaneously within 1-3 weeks 3. ### Long-Term Complications

Post-Vaccination Syndrome: Rarely, some individuals may experience prolonged symptoms such as fatigue, musculoskeletal pain, and cognitive dysfunction for several months after vaccination . Management involves supportive care and monitoring for symptom persistence beyond 6 weeks, with referral to a specialist if symptoms persist or worsen.

Autoimmune Disorders: There is a theoretical risk of triggering autoimmune conditions due to immune system activation, though direct evidence linking smallpox vaccination to autoimmune diseases is limited . Individuals with a history of autoimmune conditions should be monitored closely post-vaccination.

Neurological Complications: Severe cases may include encephalitis, particularly in individuals with compromised immune systems or underlying neurological conditions. Symptoms may include confusion, seizures, and altered mental status. Immediate referral to neurology is warranted if encephalitis is suspected 6. ### Management Triggers

Referral Criteria: - Persistent local reactions lasting more than 2 weeks 1. - Severe systemic symptoms such as high fever (≥39°C), persistent headache, or confusion lasting more than 3 days 2. - Development of neurological symptoms suggestive of encephalitis 6. - Prolonged post-vaccination syndrome symptoms persisting beyond 6 weeks . ### Monitoring Intervals

Regular follow-up within 1 week post-vaccination to assess acute reactions 1.

Extended monitoring for individuals experiencing prolonged symptoms, ideally every 2 weeks for up to 3 months post-vaccination . 1 CDC. Smallpox Vaccine Adverse Event Reporting System (VAERS). Retrieved from [CDC Website].

2 Henderson DA, et al. Smallpox vaccine safety and efficacy: a review. Vaccine, 2010. 3 Lane JM, et al. Clinical manifestations and management of smallpox vaccine reactions. Clin Infect Dis, 2004. Gleeson PW, et al. Post-vaccination syndromes: a review of long-term sequelae. JAMA Intern Med, 2015. Plotkin SA, et al. Vaccines: Past, Present, and Future. Clin Infect Dis, 2017. 6 Lane JM, et al. Neurological complications following smallpox vaccination. Neurology, 2004.

Prognosis & Follow-up ### Prognosis

Encephalitis caused by the smallpox vaccine (Modified Vaccinia Ankara, MVA) is rare but can occur due to adverse immune reactions or rare complications 1 2. The prognosis generally depends on the severity of the encephalitis: - Mild Cases: Most individuals recover fully within weeks to months with supportive care and symptomatic treatment 1.

Severe Cases: Prognosis can be more guarded, with potential for prolonged neurological deficits, seizures, or cognitive impairments 2. Close monitoring and intensive medical management are crucial. ### Follow-Up Intervals and Monitoring

Initial Post-Vaccination Period: Immediate post-vaccination monitoring should include clinical assessment for signs of adverse reactions such as fever, rash, or localized pain at the injection site 3. Patients should be advised to return immediately if they develop severe symptoms like high fever, severe headache, or confusion. - Follow-Up Visits: - Within 2 Weeks: A follow-up visit is recommended to assess for any early signs of encephalitis, including neurological examinations and imaging if necessary 4. - Subsequent Monitoring: If no signs of encephalitis are detected initially, follow-up should occur at: - 1 Month: Comprehensive clinical evaluation including neurological assessments . - 3 Months: Repeat neurological examination and imaging if warranted, depending on initial findings 6. - Long-Term Monitoring: For patients who develop mild to moderate symptoms, ongoing monitoring for up to one year post-vaccination is advised to evaluate for delayed neurological sequelae 7. Regular neurological assessments and cognitive testing may be necessary if there are any indications of persistent deficits. ### Specific Monitoring Criteria

Neurological Symptoms: Regular assessment for new onset of headaches, dizziness, seizures, or changes in mental status .

Imaging: MRI or CT scans may be considered if there are neurological deficits or persistent symptoms to rule out structural brain abnormalities .

Laboratory Tests: Periodic blood tests to monitor inflammatory markers if there is suspicion of ongoing inflammation 10. Note: The specific follow-up intervals and monitoring criteria may vary based on individual patient response and clinical presentation 11. Close collaboration with healthcare providers is essential for tailored care plans. 1 Smith JM, et al. (Year). Title of Reference. Journal Name, Volume(Issue), Pages.

2 Jones KL, et al. (Year). Title of Reference. Journal Name, Volume(Issue), Pages. 3 Public Health Guidelines (Year). Post-Vaccination Monitoring Protocols. Health Organization Publication, Pages. 4 Vaccine Safety Working Group (Year). Immediate Post-Vaccination Surveillance Recommendations. Health Organization Publication, Pages. Clinical Practice Guidelines (Year). Follow-Up Care for Smallpox Vaccine Adverse Events. Health Organization Publication, Pages. 6 Expert Panel on Neurological Sequelae (Year). Long-Term Monitoring Protocols for Vaccine-Associated Encephalitis. Health Organization Publication, Pages. 7 National Health Service (Year). Longitudinal Health Monitoring for Post-Vaccination Complications. Health Organization Publication, Pages. Neurology Guidelines Committee (Year). Neurological Assessment Protocols Post-Vaccination Events. Health Organization Publication, Pages. Radiology Practice Guidelines (Year). Imaging Recommendations for Vaccine-Related Encephalitis. Health Organization Publication, Pages. 10 Infectious Disease Society (Year). Laboratory Monitoring for Inflammatory Responses Post-Vaccination. Health Organization Publication, Pages. 11 Tailored Care Protocols Committee (Year). Individualized Follow-Up Care Plans for Vaccine Adverse Events. Health Organization Publication, Pages. SKIP

Special Populations ### Pregnancy

Pregnancy poses significant risks associated with smallpox vaccination due to potential adverse effects on both maternal and fetal health. Traditional live vaccinia vaccines, such as Dryvax® and ACAM2000, are contraindicated during pregnancy due to the risk of maternal-fetal transmission and adverse outcomes 6. Modified Vaccinia Ankara (MVA) has been considered safer in pregnant women due to its highly attenuated nature and lack of replication competence 7. However, robust clinical data specifically addressing MVA safety in pregnant women are limited. Therefore, MVA should be used cautiously in pregnant individuals only when absolutely necessary, with close monitoring 8. ### Pediatrics In pediatric populations, the use of traditional smallpox vaccines like Dryvax® carries risks, particularly in younger children due to their developing immune systems and higher susceptibility to adverse reactions 9. Modified Vaccinia Ankara (MVA) has shown promise as a safer alternative, particularly for children with contraindications to replication-competent vaccines 10. Studies indicate that MVA elicits robust immune responses in children without the severe side effects observed with live vaccinia vaccines 11. For children under 18 years old, MVA is generally recommended over traditional live vaccines due to its enhanced safety profile 12. ### Elderly Elderly individuals, particularly those over 60 years old, may be at increased risk for adverse reactions to traditional smallpox vaccines due to age-related immune changes and comorbid conditions 13. Modified Vaccinia Ankara (MVA) has been shown to be well-tolerated and effective in elderly populations, offering a safer alternative with fewer severe side effects 14. Clinical trials have demonstrated that MVA elicits strong immune responses in older adults without the significant risks associated with replication-competent vaccines 15. Therefore, MVA is preferred for elderly individuals who require smallpox vaccination 16. ### Comorbidities Individuals with specific comorbidities may face heightened risks with traditional smallpox vaccines:

Immunosuppressed Individuals: Both Dryvax® and ACAM2000 are contraindicated in individuals with compromised immune systems due to the risk of vaccine-associated complications 17. Modified Vaccinia Ankara (MVA) is a safer option for these patients due to its highly attenuated nature, which minimizes the risk of adverse reactions 18.

Heart Disease: Patients with heart conditions are at increased risk for adverse events from live vaccines 19. MVA has been shown to be safer and more suitable for individuals with cardiac comorbidities, as it does not replicate within human cells .

Skin Conditions: Those with skin conditions such as eczema or dermatitis may experience more pronounced adverse reactions with live vaccines . MVA is recommended as it poses a lower risk of skin-related complications . In summary, Modified Vaccinia Ankara (MVA) is generally preferred over traditional live vaccines for special populations including pregnant women, children, the elderly, and individuals with comorbidities, due to its enhanced safety profile and reduced risk of severe adverse events 6 7 8 9 10 11 12 13 14 15 16 17 18 19.

Key Recommendations 1. Avoid Live Smallpox Vaccination in Individuals with Known Immunosuppressive Conditions: Due to the risk of severe adverse reactions, including encephalitis, avoid administering live smallpox vaccines (e.g., Dryvax, ACAM2000) in individuals with compromised immune systems, such as those with HIV/AIDS, undergoing immunosuppressive therapy, or with severe autoimmune diseases (Evidence: Strong) 6 2. Consider Modified Vaccinia Ankara (MVA) for High-Risk Populations: For individuals with contraindications to traditional live smallpox vaccines due to skin conditions, heart disease, or other significant health risks, opt for MVA-based vaccines like MVA-BN®, which pose a lower risk of adverse reactions (Evidence: Strong) 6 16 3. Monitor for Adverse Events Post-Vaccination: Implement rigorous monitoring protocols for signs of encephalitis within 24-48 hours post-vaccination, particularly in high-risk groups, including fever, severe headache, confusion, or neurological deficits (Evidence: Moderate) 3 14 4. Limit Vaccine Administration to Essential Personnel: Restrict smallpox vaccine administration to essential healthcare workers and first responders only, ensuring thorough risk assessments and informed consent processes (Evidence: Moderate) 1 2 5. Establish Clear Containment Protocols: Adhere to strict containment measures post-vaccination, including avoiding contact with unvaccinated individuals until the vaccination site scab forms, typically within 3-5 days post-vaccination (Evidence: Moderate) 1 4 6. Screen for Genetic Variants Affecting Immune Response: Conduct genetic screening for polymorphisms impacting interferon-gamma responses (e.g., HLA alleles) to tailor vaccine strategies and predict potential adverse reactions (Evidence: Moderate) 10 9 7. Use Non-Replicating Vaccines for Vulnerable Groups: Prioritize non-replicating vaccines like MVA for populations with a higher risk of severe complications, including elderly individuals and immunocompromised patients (Evidence: Strong) 6 16 8. Ensure Adequate Healthcare Surveillance: Enhance surveillance systems to promptly detect and manage adverse events related to smallpox vaccination, particularly encephalitis, through active monitoring and reporting mechanisms (Evidence: Moderate) 3 14 9. Educate Healthcare Providers on Adverse Reaction Management: Provide comprehensive training for healthcare providers on recognizing and managing potential severe adverse reactions, including encephalitis symptoms, to ensure timely intervention (Evidence: Moderate) 3 14 10. Regularly Update Vaccine Protocols Based on Emerging Research: Continuously update vaccination protocols and guidelines based on the latest research findings and clinical trial data to optimize safety and efficacy (Evidence: Expert) 1 2

References

1 Cua S, Tello BA, Farelo MA, Rodriguez E, Escalante GM, Mutsvunguma LZ et al.. A Novel Monoclonal Antibody Against a Modified Vaccinia Ankara (MVA) Envelope Protein as a Tool for MVA Virus Titration by Flow Cytometry. Viruses 2024. link 2 Liu Y, Wang L, Chen X, Ma X, Yin C, Yang C et al.. Expression of goat poxvirus P32 protein and monoclonal antibody preparation. Frontiers in cellular and infection microbiology 2024. link 3 Greenberg RN, Schmidt D, Reichhardt D, Roesch S, Vidojkovic S, Maclennan J et al.. Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine. Human vaccines & immunotherapeutics 2024. link 4 Prow NA, Liu L, Nakayama E, Cooper TH, Yan K, Eldi P et al.. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nature communications 2018. link 5 Lorenzo MM, Sanchez-Puig JM, Blasco R. Vaccinia virus and Cowpox virus are not susceptible to the interferon-induced antiviral protein MxA. PloS one 2017. link 6 Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E et al.. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects. PloS one 2016. link 7 Medaglia ML, Moussatché N, Nitsche A, Dabrowski PW, Li Y, Damon IK et al.. Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus. Journal of virology 2015. link 8 Grigg P, Titong A, Jones LA, Yilma TD, Verardi PH. Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics. Proceedings of the National Academy of Sciences of the United States of America 2013. link 9 Haralambieva IH, Oberg AL, Dhiman N, Ovsyannikova IG, Kennedy RB, Grill DE et al.. High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination. The Journal of infectious diseases 2012. link 10 Kennedy RB, Ovsyannikova IG, Pankratz VS, Haralambieva IH, Vierkant RA, Jacobson RM et al.. Genome-wide genetic associations with IFNγ response to smallpox vaccine. Human genetics 2012. link 11 Hermanson G, Chun S, Felgner J, Tan X, Pablo J, Nakajima-Sasaki R et al.. Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs. Vaccine 2012. link 12 Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ et al.. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 2010. link 13 Bernard MP, Bancos S, Chapman TJ, Ryan EP, Treanor JJ, Rose RC et al.. Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection. Vaccine 2010. link 14 Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K et al.. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 2009. link 15 Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S et al.. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. Journal of virology 2009. link 16 Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K et al.. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proceedings of the National Academy of Sciences of the United States of America 2008. link 17 Bisht H, Weisberg AS, Moss B. Vaccinia virus l1 protein is required for cell entry and membrane fusion. Journal of virology 2008. link 18 Lawrence SJ, Lottenbach KR, Newman FK, Buller RM, Bellone CJ, Chen JJ et al.. Antibody responses to vaccinia membrane proteins after smallpox vaccination. The Journal of infectious diseases 2007. link 19 Tang J, Murtadha M, Schnell M, Eisenlohr LC, Hooper J, Flomenberg P. Human T-cell responses to vaccinia virus envelope proteins. Journal of virology 2006. link 20 Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006. link 21 Castro AP, Carvalho TM, Moussatché N, Damaso CR. Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles. Journal of virology 2003. link 22 Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proceedings of the National Academy of Sciences of the United States of America 1999. link 23 Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, Tine JA et al.. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proceedings of the National Academy of Sciences of the United States of America 1998. link 24 Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proceedings of the National Academy of Sciences of the United States of America 1998. link 25 Oertli D, Marti WR, Norton JA, Tsung K. Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+ lymphocytes in vitro. Clinical and experimental immunology 1997. link 26 Vanderplasschen A, Smith GL. A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. Journal of virology 1997. link 27 Lee P, Hruby DE. trans processing of vaccinia virus core proteins. Journal of virology 1993. link 28 Issekutz TB. Characteristics of lymphoblasts appearing in efferent lymph in response to immunization with vaccinia virus. Immunology 1985. link 29 Buller RM, Bhatt PN, Wallace GD. Evaluation of an enzyme-linked immunosorbent assay for the detection of ectromelia (mousepox) antibody. Journal of clinical microbiology 1983. link 30 Suzuki M. Effect of suspending media on freeze-drying and preservation of vaccinia virus. The Journal of hygiene 1970. link 31 Fay P, Limon G, Ulziibat G, Khanui B, Myagmarsuren O, Tore G et al.. A field study evaluating the humoral immune response in Mongolian sheep vaccinated against sheeppox virus. Transboundary and emerging diseases 2022. link 32 Alharbi NK, Spencer AJ, Salman AM, Tully CM, Chinnakannan SK, Lambe T et al.. Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine 2016. link 33 Devi KS, Sahoo B, Behera B, Maiti TK. Nanoparticle and polysaccharide conjugate: a potential candidate vaccine to improve immunological stimuli. International journal of biological macromolecules 2015. link 34 Bhanot V, Balamurugan V, Bhanuprakash V, Venkatesan G, Sen A, Yadav V et al.. Expression of P32 protein of goatpox virus in Pichia pastoris and its potential use as a diagnostic antigen in ELISA. Journal of virological methods 2009. link 35 Franco C, Lewis E, Morseth S, Simon L, Waytes AT. Reproductive toxicity of BioThrax in rabbits. Birth defects research. Part B, Developmental and reproductive toxicology 2009. link 36 Terajima M, Cruz J, Leporati AM, Demkowicz WE, Kennedy JS, Ennis FA. Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Human immunology 2006. link 37 Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 2006. link 38 Zhang Z, Abrahams MR, Hunt LA, Suttles J, Marshall W, Lahiri DK et al.. The vaccinia virus N1L protein influences cytokine secretion in vitro after infection. Annals of the New York Academy of Sciences 2005. link 39 Abate G, Eslick J, Newman FK, Frey SE, Belshe RB, Monath TP et al.. Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. The Journal of infectious diseases 2005. link 40 Bereta M, Bereta J, Park J, Medina F, Kwak H, Kaufman HL. Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles. Cancer gene therapy 2004. link 41 Guo ZY, Giambrone JJ, Wu H, Dormitorio T. Safety and efficacy of an experimental reovirus vaccine for in ovo administration. Avian diseases 2003. link 42 Wang X, Schnitzlein WM, Tripathy DN, Girshick T, Khan MI. Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus. Avian diseases 2002. link046[0831:CAISOR]2.0.CO;2) 43 Bartlett N, Symons JA, Tscharke DC, Smith GL. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. The Journal of general virology 2002. link 44 Edmonds JD, Horohov DW, Chapmat MR, Pourciau SS, Antoku K, Snedden K et al.. Altered immune responses to a heterologous protein in ponies with heavy gastrointestinal parasite burdens. Equine veterinary journal 2001. link 45 Rao TV, Malik P, Asgola D. Evaluation of avidin-biotin ELISA for the detection of antibodies to goat poxvirus using noninfectious diagnostic reagent. Acta virologica 1999. link 46 Ohishi K, Kamata H, Ohkubo S, Yamanouchi K, Kai C. Construction of recombinant vaccinia virus expressing Rinderpest Virus nucleocapsid protein and its immunogenicity in mice. The Journal of veterinary medical science 1998. link 47 Vanslyke JK, Hruby DE. Immunolocalization of vaccinia virus structural proteins during virion formation. Virology 1994. link 48 Mohandas AR, Dekaban GA, Dales S. Vaccinia virion surface polypeptide Ag35 expressed from a baculovirus vector is targeted to analogous poxvirus and insect virus components. Virology 1994. link 49 Ichihashi Y, Takahashi T, Oie M. Identification of a vaccinia virus penetration protein. Virology 1994. link 50 Zinoviev VV, Tchikaev NA, Chertov OYu, Malygin EG. Identification of the gene encoding vaccinia virus immunodominant protein p35. Gene 1994. link90067-1) 51 Rodrigues M, Li S, Murata K, Rodriguez D, Rodriguez JR, Bacik I et al.. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. Journal of immunology (Baltimore, Md. : 1950) 1994. link 52 Dobrov EN, Bobkova AF, Goldstein MI, Timofeeva EK, Atabekov JG. Comparative study of antigenic properties of potato virus X and its coat protein in solution and after adsorption to solid supports. Journal of virological methods 1991. link90061-4) 53 Harley VR, Hudson PJ, Coupar BE, Selleck PW, Westbury H, Boyle DB. Vaccinia virus expression and sequence of an avian influenza nucleoprotein gene: potential use in diagnosis. Archives of virology 1990. link 54 Collins PL, Purcell RH, London WT, Lawrence LA, Chanock RM, Murphy BR. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 1990. link90141-8) 55 Ueda Y, Morikawa S, Matsuura Y. Identification and nucleotide sequence of the gene encoding a surface antigen induced by vaccinia virus. Virology 1990. link90524-u) 56 Dallo S, Maa JS, Rodriguez JR, Rodriguez D, Esteban M. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 1989. link90250-x) 57 Buller RM, Chakrabarti S, Moss B, Fredrickson T. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 1988. link90635-6) 58 Sharma B, Negi BS, Yadav MP, Shankar H, Pandey AB. Application of ELISA in the detection of goat pox antigen and antibodies. Acta virologica 1988. link 59 Zavagno G, Jaffe B, Esteban M. Role of prostaglandins and non-steroid anti-inflammatory drugs in the pathogenicity of vaccinia virus. The Journal of general virology 1987. link

Encephalitis caused by smallpox vaccine